Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT04840511
Active, not recruiting Not applicable

The Effect of Perioperative Lidocaine Infusion on Neutrophil Extracellular Trapping

NCT04840511 · tracked via the Priya Life Science South Korea tracker
Sponsor
The Catholic University of Korea
Phase
Not applicable
Started
2021-09-27
Last updated
2023-01-13

Condition(s) studied

Urologic Cancer

Investigational drug(s) / intervention(s)

lidocaine group →control group

lidocaine group: lidocaine 1.5 mg/kg bolus (infused over 10 min) followed by 2.0 mg/kg/h during operation and 1.0 mg/kg/h during postoperative 24 hours (no more than 120 mg/h)

control group: normal saline 0.15 ml bolus followed by 0.2 ml/kg/hr during operation and 0.1 ml/kg/hr during postoperative 24 hours

Study summary

This study will be done to investigate perioperative lidocaine infusion on neutrophil extracellular trapping in the patients undergoing the robot-assisted prostatectomy.

Eligibility

Sex
MALE
Min age
20 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * patients scheduled robot-assisted prostatectomy Exclusion Criteria: * lidocaine allergy Hx * hemodynamic unstable patients * weight \< 40kg * arrhythmia or bradycardia

Primary outcome measure(s)

  • Concentration of citrullinated histone3 — 24 hours after surgery
    This will be obtained using ELISA.

Trial sites (1)

FacilityCityRegionStatus
Seoul St.Mary's Hospital Seoul Seocho-gu

More The Catholic University of Korea trials in South Korea

Clinical Impact of Orsiro™ Stent in Patient With Chronic Kidney Disease Active, not recruiting
Craving Management Program for Substance Use Disorders Starting soon
Role of FFR in ACS Patients: Pressure ACS Registry Active, not recruiting
Emotion Regulation Program for Substance Use Disorders Starting soon
First Step Program for Substance Use Disorders Starting soon

Other trials for the same condition

Prediction of Myocardial Injury After Non-Cardiac Surgery in Urologic Cancer Patients Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04840511 on ClinicalTrials.gov ↗ ← All trials in South Korea